BONNEY MICHAEL W 4

What Happened Michael W. Bonney, a director of IMMUNIC, Inc. (IMUX), was granted 100,000 options to purchase common stock, reported on Form 4 dated June 29, 2026. The filing lists the options with a $0.00 price per share (derivative award) and shows the grant as an acquisition (transaction code A). This is a grant of equity compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: June 29, 2026; Form filed same day (no late filing indicated).
• Instrument: Options to purchase 100,000 shares (derivative award) reported at $0.00 per share.
• Vesting: Options vest in 36 equal monthly installments beginning May 15, 2026 (per footnote).
• Approval: Options were conditionally approved by the Board on May 15, 2026 and required (and received) stockholder approval of an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the June 29, 2026 annual meeting (per footnote).
• Shares owned after the transaction: Not specified in the Form 4 filing.

Context This filing documents a grant of options (not an exercise or share sale). As a derivative award, these options do not represent immediate stock ownership and will only convert into shares as they vest and are exercised. The $0.00 figure is what the Form 4 reports for the award; the filing does not provide a cash value or indicate any immediate sale. Grants to directors are common compensation for service and should be considered informational rather than predictive of future company performance.